What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Breast cancer
Breast cancer, Internal medicine, Oncology, Cancer and Neoadjuvant therapy are his primary areas of study.
His Breast cancer research incorporates elements of Immunology, Cancer research, Clinical trial and Chemotherapy.
His work on Internal medicine is being expanded to include thematically relevant topics such as Gynecology.
His Oncology research is multidisciplinary, incorporating perspectives in Randomized controlled trial, Surgery, Pathology, Gene expression profiling and Triple-negative breast cancer.
The concepts of his Cancer study are interwoven with issues in Mutation and AKT1, Protein kinase B.
His work deals with themes such as Survival rate, Prospective cohort study and Chemotherapy regimen, which intersect with Neoadjuvant therapy.
His most cited work include:
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer (1820 citations)
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy (1509 citations)
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy (852 citations)
What are the main themes of his work throughout his whole career to date?
W. Fraser Symmans mostly deals with Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy.
His Breast cancer research is multidisciplinary, relying on both Cancer research, Surgery and Pathology.
His studies deal with areas such as Clinical trial, Trastuzumab, Cyclophosphamide, Triple-negative breast cancer and Cohort as well as Oncology.
W. Fraser Symmans has researched Cancer in several fields, including Phenotype and Endocrinology.
The various areas that W. Fraser Symmans examines in his Chemotherapy study include Anthracycline and Predictive marker.
His Neoadjuvant therapy research integrates issues from Regimen and Clinical endpoint.
He most often published in these fields:
- Breast cancer (70.85%)
- Internal medicine (56.78%)
- Oncology (54.77%)
What were the highlights of his more recent work (between 2018-2021)?
- Breast cancer (70.85%)
- Internal medicine (56.78%)
- Oncology (54.77%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Breast cancer, Internal medicine, Oncology, Cancer and Neoadjuvant therapy.
His Breast cancer study incorporates themes from Outcome data, Regimen, Transcriptome, Targeted therapy and Stage.
His Internal medicine and Chemotherapy, MammaPrint, Clinical trial, Clinical endpoint and Proportional hazards model investigations all form part of his Internal medicine research activities.
His Oncology study combines topics in areas such as Guideline, Triple-negative breast cancer, Trastuzumab and Cohort.
His Cancer research includes themes of High risk patients, Gynecology and Therapeutic regimen.
As a part of the same scientific family, he mostly works in the field of Neoadjuvant therapy, focusing on Randomized controlled trial and, on occasion, Progression-free survival and Confirmatory trial.
Between 2018 and 2021, his most popular works were:
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. (93 citations)
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial (90 citations)
- Estrogen and progesterone receptor testing in breast cancer: American society of clinical oncology/college of American pathologists guideline update (40 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Breast cancer
His primary areas of investigation include Breast cancer, Internal medicine, Oncology, Neoadjuvant therapy and Guideline.
W. Fraser Symmans works mostly in the field of Breast cancer, limiting it down to concerns involving Gene and, occasionally, Concordance correlation coefficient.
His work on Predictive biomarker, Stromal tumor and Metastatic breast cancer as part of general Internal medicine research is frequently linked to Educational resources and Clinical Practice, thereby connecting diverse disciplines of science.
His biological study spans a wide range of topics, including Phenotype, Hormone receptor, Hormone, Genotype and Estrogen receptor alpha.
His Neoadjuvant therapy research incorporates themes from Randomized controlled trial, Proportional hazards model and Chemotherapy regimen, Chemotherapy.
His Guideline study also includes
- Estrogen that intertwine with fields like Immunohistochemistry, Carcinoma, Estrogen receptor and Clinical Oncology,
- Receptor that intertwine with fields like Progesterone metabolism.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
